VEGFA and neoplasm: Overall, the present study may contribute to future innovative clinical applications and suggests that the VEGF tumour level is a possible predictor for ZD6126 antitumour efficacy, that it strengthens the notion of antitumour supra-additive effects when combining gefitinib and ZD6126, identifies neoangiogenesis as the main impact of this synergistic combination and gives no firm support to the benefit of adding RT to the drug association.